Page last updated: 2024-08-21

pyrazines and Leiomyosarcoma

pyrazines has been researched along with Leiomyosarcoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Baird, JD; Branstrom, A; Cao, L; Colacino, JM; Dali, M; Dumble, M; Furia, B; Jernigan, F; Kim, MJ; Kong, R; Laskin, OL; Mollin, A; Moon, YC; Mühlethaler, T; O'Keefe, K; Prota, AE; Pykett, M; Sheedy, J; Sheridan, R; Spiegel, RJ; Steinmetz, MO; Weetall, M	1

Trials

1 trial(s) available for pyrazines and Leiomyosarcoma

Article	Year
Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent. Molecular cancer therapeutics, 2021, Volume: 20, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Benzimidazoles; Cell Proliferation; Female; Glioblastoma; Humans; Leiomyosarcoma; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Middle Aged; Prognosis; Pyrazines; Tissue Distribution; Tubulin Modulators; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2021

Article

Year

Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent.

Molecular cancer therapeutics, 2021, Volume: 20, Issue:10

Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Benzimidazoles; Cell Proliferation; Female; Glioblastoma; Humans; Leiomyosarcoma; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Middle Aged; Prognosis; Pyrazines; Tissue Distribution; Tubulin Modulators; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2021